{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:38:31Z","timestamp":1791563911112,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T00:00:00Z","timestamp":1487030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ekir.2017.01.016","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T05:16:36Z","timestamp":1487654196000},"page":"634-644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism"],"prefix":"10.1016","volume":"2","author":[{"given":"Keitaro","family":"Yokoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shigematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoi","family":"Odani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2017.01.016_bib1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.01.016_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","article-title":"Hyperparathyroidism","volume":"374","author":"Fraser","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2017.01.016_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ki.1995.292","article-title":"The pathogenesis of parathyroid gland hyperplasia in chronic renal failure","volume":"48","author":"Dr\u00fceke","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.01.016_bib4","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/ndt\/gfn571","article-title":"Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2017.01.016_bib5","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2017.01.016_bib6","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca\u00a0\u00d7 PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"Suppl 113","key":"10.1016\/j.ekir.2017.01.016_bib7","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CDK-MBD)","volume":"76","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.01.016_bib8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1744-9987.2008.00648.x","article-title":"Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients","volume":"12","year":"2008","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.ekir.2017.01.016_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.0894-0959.2004.17308.x","article-title":"The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease","volume":"17","author":"Goodman","year":"2004","journal-title":"Semin Dial"},{"key":"10.1016\/j.ekir.2017.01.016_bib10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/366575a0","article-title":"Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid","volume":"366","author":"Brown","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ekir.2017.01.016_bib11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.ekir.2017.01.016_bib12","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ekir.2017.01.016_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1542-4758.2009.00397.x","article-title":"Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients","volume":"14","author":"Gincherman","year":"2010","journal-title":"Hemodial Int"},{"key":"10.1016\/j.ekir.2017.01.016_bib14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfm534","article-title":"Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients","volume":"23","author":"Fukagawa","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2017.01.016_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.113.204834","article-title":"Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"346","author":"Walter","year":"2013","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.ekir.2017.01.016_bib16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/jcph.314","article-title":"A\u00a0pharmacokinetic\/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects","volume":"54","author":"Shen","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ekir.2017.01.016_bib17","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/mol.115.098392","article-title":"Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action","volume":"88","author":"Alexander","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ekir.2017.01.016_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","article-title":"AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients","volume":"85","author":"Martin","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.01.016_bib19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1185\/03007995.2015.1031731","article-title":"A\u00a0randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"31","author":"Bell","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ekir.2017.01.016_bib20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000442754","article-title":"Treatment of secondary hyperparathyroidism: results of a phase 2 trial evaluating an intravenous peptide agonist of the calcium-sensing receptor","volume":"42","author":"Bushinsky","year":"2015","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2017.01.016_bib21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study","volume":"10","author":"Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.01.016_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2215\/CJN.01760215","article-title":"Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism","volume":"11","author":"Bover","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.01.016_bib23","series-title":"Hemodialysis Therapy IX","first-page":"32","article-title":"Cinacalcet for mineral metabolism management: is it possible to achieve the goal set in the JSDT guideline?","author":"Okuno","year":"2009"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917300414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917300414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T13:26:45Z","timestamp":1658669205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024917300414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S2468024917300414"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2017.01.016","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2017.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}